FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for RosaceaEmrosi Initial Distribution Ongoing; First ...

Investigators sought to better understand how race and ethnicity was related to the severity of rosacea phenotypes among adults.

Journey Medical (DERM) announced the launch of and the first prescriptions filled for Emrosi(TM) (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended ...

Emrosi™ (minocycline hydrochloride extended-release capsules) is now available for the treatment of inflammatory lesions (papules and pustules) of rosacea ...

A study found that DFD-29 was more effective than both doxycycline and placebo, with a favorable risk-benefit profile for ...

Small amounts of a common antibiotic and anti-inflammatory drug can curb symptoms where a misplaced immune reaction (e.g., ...

“The results of these placebo-controlled randomized clinical trials demonstrate that minocycline is efficacious and provides significantly superior outcomes in rosacea compared with placebo and ...

If you have rosacea, you must be experiencing redness and small, red bumps on your face for a long time. These symptoms may last for a few weeks or months and then disappear for a while. The problem ...

In the Minocycline Versus Oracea® in Rosacea-1 (MVOR-1) and Minocycline Versus Oracea in Rosacea-2 (MVOR-2) trials, subjects were randomized to receive DFD-29, Oracea, or placebo. The co-primary ...

In the Minocycline Versus Oracea® in Rosacea-1 (MVOR-1) and Minocycline Versus Oracea in Rosacea-2 (MVOR-2) trials, subjects were randomized to receive DFD-29, Oracea, or placebo. The co-primary ...

U.S. FDA approved Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults ...